Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age Related Macular Degeneration

Interventions: Drug: RTH258

First Posted Date: 2019-04-29

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT03930641

Locations: 🇺🇸
Novartis Investigative Site, Richmond, Virginia, United States

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Phase 2

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: LKA651
Drug: Lucentis

First Posted Date: 2019-04-25

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 91

Registration Number: NCT03927690

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

This Was a Dose-finding Study to Evaluate Efficacy and Safety of LOU064 in Patients With CSU Inadequately Controlled by H1-antihistamines

Phase 2

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: LOU064 Arm 1
Drug: LOU064 Arm 2
Drug: LOU064 Arm 5
Drug: LOU064 Arm 4
Drug: Placebo arm
Drug: LOU064 Arm 3
Drug: LOU064 Arm 6

First Posted Date: 2019-04-24

Last Posted Date: 2022-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 311

Registration Number: NCT03926611

Locations: 🇬🇧
Novartis Investigative Site, Plymouth, United Kingdom

Single Dose and Multiple Dose Study to Assess Safety and Tolerability of LOU064

Phase 1

Completed

Conditions: Healthy Volunteers, Atopic Diathesis and Atopic Dermatitis

Interventions: Drug: LOU064
Drug: Placebo

First Posted Date: 2019-04-18

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 185

Registration Number: NCT03918980

Locations: 🇳🇱
Novartis Investigative Site, Leiden, Netherlands

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

Phase 3

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Brolucizumab
Drug: Aflibercept

First Posted Date: 2019-04-17

Last Posted Date: 2022-08-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 517

Registration Number: NCT03917472

Locations: 🇸🇰
Novartis Investigative Site, Zvolen, Slovakia

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure

Phase 3

Completed

Conditions: Heart Failure
Erectile Dysfunction
Heart Failure, Systolic

Interventions: Drug: LCZ696
Drug: Enalapril matching placebo
Drug: LCZ696 matching placebo
Drug: Enalapril

First Posted Date: 2019-04-17

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT03917459

Locations: 🇩🇪
Novartis Investigative Site, Wermsdorf, Germany

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Phase 3

Terminated

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions: Drug: LCZ696

First Posted Date: 2019-04-10

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT03909295

Locations: 🇯🇵
Novartis Investigative Site, Shinagawa-ku, Tokyo, Japan

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Phase 3

Completed

Conditions: Chronic Spontaneous Urticaria

Interventions: Biological: Ligelizumab

First Posted Date: 2019-04-09

Last Posted Date: 2024-03-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT03907878

Locations: 🇯🇵
Novartis Investigative Site, Hiroshima, Japan

AScalate: Treat-to-target in Axial Spondyloarthritis

Phase 3

Completed

Conditions: Axial Spondyloarthritis

Interventions: Biological: Secukinumab/Adalimumab-Biosimilar
Other: Standard-of-care

First Posted Date: 2019-04-08

Last Posted Date: 2023-07-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 305

Registration Number: NCT03906136

Locations: 🇩🇪
Novartis Investigative Site, Ulm, Germany

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

Phase 2

Completed

Conditions: Sjögren Syndrome

Interventions: Drug: CFZ533
Other: Placebo

First Posted Date: 2019-04-05

Last Posted Date: 2023-09-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 273

Registration Number: NCT03905525

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy